Liege, Belgium, 12 September 2023 – 5:45 pm CEST – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra“), a company dedicated to Women’s Health, confirms to Bondholders that, in accordance with the terms and conditions of the Company’s EUR 125,000,000 senior unsecured convertible bonds due 2025 (ISIN: BE6325746855) (the “Bonds”), as a result of the issuance of 10 million new ordinary shares at a price of EUR 2.00 each, as part of the private placement announced on 24 August 2023, pursuant to Condition 5(b)(vi), the Conversion Price of the Bonds has been adjusted from EUR 23.8262 to EUR 23.2370, effective as of 28 August 2023.
Capitalised terms not otherwise defined herein shall have the meanings given to them in the terms and conditions of the Bonds.